Secondary predictors of ovarian hyperstimulation syndrome development
DOI:
https://doi.org/10.14739/2310-1210.2019.6.186502Keywords:
ovarian hyperstimulation syndrome, prognosis, preovulatory follicles, oocytes, estradiol, vascular endothelial growth factor, interleukin‑6Abstract
In the treatment of infertility by the method of fertilization in vitro, such a serious complication as ovarian hyperstimulation syndrome (OHSS) can occur. Primary predictors of OHSS development are widely used in practice while selecting controlled ovarian stimulation patterns. The identification and evaluation of secondary predictors of OHSS development is relevant.
Aim. To identify and evaluate secondary predictors of OHSS in women at high risk of OHSS.
Materials and methods. The study included 240 women at high risk of developing ovarian hyperstimulation syndrome, 63 of these women subsequently developed ovarian hyperstimulation syndrome, and 177 did not. To identify secondary predictors, a number of preovulatory follicles and oocytes was evaluated, estradiol levels, vascular endothelial growth factor (VEGF) and interleukin‑6 (IL‑6) were defined in the blood serum and follicular fluid.
Results. Compared to women without OHSS, there was a statistically significant increase in the number of preovulatory follicles, oocytes, estradiol, VEGF, IL‑6 in the blood serum and follicular fluid in OHSS patients. There was a direct correlation between the serum and follicular fluid levels of estradiol (rs = 0.85; 95 % CI 0.80–0.89; P < 0.001), VEGF (rs = 0.76; 95 % CI 0.69–0.81; P < 0.001) and IL‑6 (rs = 0.67; 95 % CI 0.58–0.74; P < 0.001). Secondary predictors of OHSS was the number of preovulatory follicles ≥30 for two ovary (sensitivity – 46.0 %, specificity – 91.0 %), the number of oocytes ≥19 (sensitivity – 87.3 %, specificity – 97.7 %), serum estradiol levels ≥4800 pg/ml (sensitivity – 74.6 %, specificity – 96.6 %) and estradiol in follicular fluid – ≥725000 pg/ml (sensitivity – 98.4 %, specificity – 97.7 %), serum VEGF ≥ 30 pg/ml (sensitivity – 76.2 %, specificity – 98.3 %) and VEGF in follicular fluid ≥500 pg/ml (sensitivity – 87.3 %, specificity – 97.2 %), IL‑6 in serum ≥4 pg/ml (sensitivity – 65.1 %, specificity – 98.9 %) and IL‑6 in follicular fluid ≥8.5 pg/ml (sensitivity – 90.5 %, specificity – 98.3 %), respectively.
Conclusions. The predictors of OHSS should be taken into account to reduce the risk of its development. In identifying secondary predictors of OHSS development, it is necessary to use preventive measures consisting in discontinuation of luteal phase support, vitrification of all embryos and their transfer in subsequent thawed cycles.
References
Yuzko, O. M. (2016). Dopomizhni reproduktyvni tekhnolohii Ukrainy – 25 rokiv uspikhu [Assisted reproductive technologies of Ukraine – 25 years of success]. Zbirnyk naukovykh prats Asotsiatsii akusheriv-hinekolohiv Ukrainy, 2(38), 393-396. [in Ukrainian].
Datta, J., Palmer, M., Tanton, C., Gibson, L., Jones, K., & Macdowall, W. et al. (2016). Prevalence of infertility and help seeking among 15 000 women and men. Human Reproduction, 31(9), 2108-2118. doi: 10.1093/humrep/dew123
Mirzaei, M., Namiranian, N., Dehghani Firouzabadi, R., & Gholami, S. (2018). The prevalence of infertility in 20-49 years women in Yazd, 2014-2015: A cross-sectional study. International Journal of Reproductive Biomedicine (Yazd), 16(11), 683-688.
Polis, C., Cox, C., Tunçalp, Ö., McLain, A., & Thoma, M. (2017). Estimating infertility prevalence in low-to-middle-income countries: an application of a current duration approach to Demographic and Health Survey data. Human Reproduction, 32(5), 1064-1074. doi: 10.1093/humrep/dex025
De Geyter, C., Calhaz-Jorge, C., Kupka, M., Wyns, C., Mocanu, E., & Motrenko, T. et al. (2018). ART in Europe, 2014: results generated from European registries by ESHRE: The European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Human Reproduction, 33(9), 1586-1601. doi: 10.1093/humrep/dey242
Schenker, J. G. (2013). Complications of Assisted Reproductive Technology. Giorn. It. Ost. Gin., XXXV(1), 110-112.
Feinberg, E. (2016). Ovarian hyperstimulation: past, present, and future. Fertility And Sterility, 106(6), 1330. doi: 10.1016/j.fertnstert.2016.08.032
Namavar Jahromi, B., Parsanezhad, M. E., Shomali, Z., Bakhshai, P., Alborzi, M., Moin Vaziri, N., et al. (2018). Ovarian hyperstimulation syndrome: a narrative review of its pathophysiology, risk factors, prevention, classification, and management. Iran J Med Sci., 43(3), 248 260.
Pfeifer, S., Butts, S., Dumesic, D., Fossum, G., Gracia, C., & La Barbera, A. et al. (2016). Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertility And Sterility, 106(7), 1634-1647. doi: 10.1016/j.fertnstert.2016.08.048
Shields, R., Vollenhoven, B., Ahuja, K., & Talmor, A. (2016). Ovarian hyperstimulation syndrome: A case control study investigating risk factors. Australian And New Zealand Journal Of Obstetrics And Gynaecology, 56(6), 624-627. doi: 10.1111/ajo.12515
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
